Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
September 3, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-005 Clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and lenvatinib compared with double placebo and lenvatinib in participants with unresectable or metastatic hepatocellular carcinoma and compensated liver function (Child-Pugh Class A) following failure of first-line treatment that included an anti-PD-(L)1 agent.
The objective of this trial is to determine how well a new investigational drug called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib. -
August 27, 2026Pamplona/MadridIn recruitmentEarly phase
XmAb541-01 Phase 1 clinical trial to evaluate XmAb541 in advanced solid tumors.
The primary objective is to evaluate the safety and tolerability of the study drug. -
August 26, 2026Pamplona/MadridIn recruitment
3138001 "Phase I/II, open-label clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ODM-216 in participants with advanced solid tumors."
This is the first time ODM-216 is being tested in humans. ODM-216 is a type of immunotherapy. It works by helping the immune system better recognize and respond to cancer. The primary objective of this study is to determine the safety and tolerability of ODM-216 and establish the optimal dose. -
August 26, 2026Pamplona/MadridIn recruitment
PEAK-1 Clinical trial to evaluate casdatifan and cabozantinib compared with placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma.
The purpose of the study is to evaluate progression-free survival (PFS) with casdatifan versus placebo, when both are administered in combination with cabozantinib, in adult patients with confirmed advanced or metastatic clear cell renal cell carcinoma who experienced disease progression during or after prior anti-PD-1 or anti-PD-L1 immunotherapy. -
August 25, 2026Pamplona/MadridIn recruitment
RMC-APEX-103 Phase I/II, open-label, multicenter clinical trial of RAS(ON) inhibitors in combination with ivonescimab, with or without other anticancer agents, in patients with solid tumors.
The purpose of this study is to test several combinations of new investigational drugs (study drugs), with chemotherapy (if you have not yet received treatment for your cancer) or without chemotherapy (if you have already received treatment for your cancer). If you have previously received treatment for colorectal cancer, you may receive the study drug or drugs together with cetuximab. -
August 23, 2026Pamplona/MadridIn recruitmentEarly phase
M24-533 Phase 2 clinical trial to evaluate the safety and efficacy of multiple treatment combinations with telisotuzumab adizutecan in participants with metastatic colorectal cancer.
The primary objective is to evaluate the efficacy of telisotuzumab adizutecan combinations compared with standard treatment in metastatic colorectal cancer (mCRC). -
August 20, 2026Pamplona/MadridIn recruitmentEarly phase
MEDOPP662 Phase II clinical trial evaluating the safety and efficacy of repotrectinib in patients with ROS1-positive non-small cell lung cancer with active brain metastases.
The primary objective of this study is to evaluate the efficacy of the study drug repotrectinib (a kinase inhibitor that blocks the activity of the abnormal ROS1 protein) in patients with NSCLC who have a ROS1 alteration and active brain metastases. -
August 19, 2026Pamplona/MadridIn recruitment
FCO-FOX-2024-01 Clinical trial to evaluate the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C combined with surgery versus surgery alone in locally advanced colorectal carcinoma (FOXHIPECT4).
The primary objective is to determine whether proactive neoadjuvant systemic treatment (FOLFOX), with or without HIPEC with mitomycin C, followed by postoperative adjuvant systemic treatment, increases 36-month disease-free survival in patients with locally advanced colon cancer compared with standard treatment. -
August 12, 2026PamplonaIn recruitment
RMC-6236-304 Phase III Study of Daraxonrasib in Patients with Resected Pancreatic Ductal Adenocarcinoma.
The purpose of this trial is to test an investigational drug called daraxonrasib (RMC-6236). Daraxonrasib is an investigational drug, which means that it has not been approved by the Spanish Agency for Medicines and Health Products (AEMPS) or by any other health authority in any country. Daraxonrasib is currently being investigated in other ongoing studies in pancreatic cancer, and its safety, tolerability, and efficacy are being evaluated in comparison with usual clinical practice. -
August 11, 2026PamplonaIn recruitment
1438-0012 Clinical trial in patients with advanced small cell lung cancer comparing treatment with obrixtamig plus atezolizumab, carboplatin, and etoposide versus standard chemotherapy.
The purpose of this clinical study is to determine whether obrixtamig in combination with atezolizumab, carboplatin, and etoposide (standard chemotherapy) is more effective than standard chemotherapy alone in treating people with advanced small cell lung cancer.